Kramer Levin provides its clients proactive, creative and pragmatic solutions that address today’s most challenging legal issues. The firm is headquartered in New York with offices in Silicon Valley and Paris and fosters a strong culture of involvement in public and community service. For more information, visit www.kramerlevin.com
Intellectual Property partner Gregory B. Sephton, special counsel Christine Willgoos and associate John P. Dillon's article "BPCIA Questions Continue To Arise For Biosimilar Applicants"...
Intellectual Property partner Gregory B. Sephton, special
counsel Christine Willgoos and associate John P. Dillon's
article "BPCIA Questions Continue To Arise For Biosimilar
Applicants" appeared in Law360 on July 24, 2017. The
article examines the Supreme Court's decision in Sandoz
Inc. v. Amgen Inc., the first case under the Biologics Price
Competition and Innovation Act of 2009.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
